Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis
Annals of the Rheumatic Diseases · 2025
DOI: 10.1016/j.ard.2025.01.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Patricia Remalante-Rayco und 8 weiteren Autor:innen. Beteiligte Einrichtung: Schroeder Arthritis Institute, Toronto Western Hospital, Spondylitis Program, University Health Network, Toronto, ON, Canada; Department of Clinical …. Hauptthemen laut MEDLINE: Antirheumatic Agents, Axial Spondyloarthritis, Biological Products, Withholding Treatment. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Race and Difference Initiative, Emory University.
Abstract (Originalsprache)
OBJECTIVES: To estimate the main and interaction effects of axial spondyloarthritis (axSpA) subtype and sex on first biologic disease-modifying antirheumatic drug (bDMARD) discontinuation. METHODS: This retrospective cohort study included nonradiographic axSpA (nr-axSpA) and radiographic axSpA (r-axSpA) patients initiating tumour necrosis factor or interleukin-17 inhibitors. Modified Poisson regressions were used to estimate risk ratios (RRs) for the association of subtype and sex with discontinuation, adjusting for baseline covariates. Interaction was assessed using the relative excess risk due to interaction (RERI) and ratio of RRs. In addition, bDMARD survival rates were analysed using Kaplan-Meier curves. RESULTS: Among 469 patients, 64% discontinued their first bDMARD. Nr-axSpA (RR, 1.80; 95% CI, 1.26-2.59) and female sex (RR, 1.49; 95% CI, 1.081-2.045) were significantly associated with discontinuation. Positive interaction trends between subtype and sex were observed on additive (RERI 0.49, 95% CI, -0.78 to 1.75) and multiplicative (RR ratio, 1.05; 95% CI, 0.55-2.03) scales, though not statistically significant. Nr-axSpA females had twice the discontinuation risk of r-axSpA males (hazard ratio, 2.30; 95% CI, 1.68-3.15, P < .001). bDMARD survival over 20 years was significantly lower in nr-axSpA and female patients. CONCLUSIONS: Nr-axSpA and female patients face a significantly higher risk of bDMARD discontinuation and shorter bDMARD survival. Although the combined effect of subtype and sex trended higher, it was not statistically significant. These findings underscore the need to address potential treatment challenges in female nr-axSpA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Schroeder Arthritis Institute, Toronto Western Hospital, Spondylitis Program, University Health Network, Toronto, ON, Canada; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manil…
- Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines; Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manil…
- Department of Biostatistics, University Health Network, Toronto, ON, Canada.
- Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
- Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
- Division of Rheumatology, Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
Förderung
- Race and Difference Initiative, Emory University
Zitieren
APA
Remalante-Rayco, P., Baja, E. S., Baskurt, Z., Chim, T., Panelo, C. I. A., Osio-Salido, E., Inman, R. D., Dans, L. F., & Haroon, N. (2025). Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.01.007
Vancouver
Remalante-Rayco P, Baja ES, Baskurt Z, Chim T, Panelo CIA, Osio-Salido E, et al. Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.01.007
BibTeX
@article{RemalanteRayco2025,
author = {Remalante-Rayco, Patricia and Baja, Emmanuel S and Baskurt, Zeynep and Chim, Tina and Panelo, Carlo Irwin A and Osio-Salido, Evelyn and Inman, Robert D and Dans, Leonila F and Haroon, Nigil},
title = {Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
doi = {10.1016/j.ard.2025.01.007}
}
EUVIMED